The story has been updated to correct the market size figure for BioFire Diagnostics' GI and respiratory tests and to correct the previous name of the company.

NEW YORK (GenomeWeb News) – Though it is a relatively new player in the molecular diagnostics space, Salt Lake City-based BioFire Diagnostics sees "tremendous opportunity" for growth during the next 12 to 24 months, its CEO said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.